CO44657_pionERA: A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Objective

Clinical Trial Details

IRB Protocol Number

2023.090

Principal Investigator(s)

Jason Jones, MD

Clinical Trial Categories

• Cancer
• Breast Cancer

Contact

Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org